Exciting news has emerged from the Phase III IMforte study, showcasing the positive impact of combining Roche’s Tecentriq with lurbinectedin for first-line maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC). The data revealed a remarkable 46% reduction in the risk of disease progression or death, along with a 27% decrease in the risk of death, offering hope in a cancer type with limited treatment options and poor survival rates. This groundbreaking study marks the first of its kind in ES-SCLC first-line maintenance to demonstrate significant enhancements in both progression-free and overall survival. Presented at the prestigious 2025 ASCO Annual Meeting and published in The Lancet, these results underscore the potential of this combination therapy to transform outcomes for individuals with ES-SCLC. The safety profile of the Tecentriq and lurbinectedin combination remained consistent with their known profiles, further solidifying the promise of this innovative approach in combating this aggressive form of lung cancer.
Read more about this — here
